GE HealthCare Technologies Inc. reported a 3% increase in revenues, reaching $4.8 billion for the first quarter of 2025, with organic revenue growth at 4%. The company's net income attributable to GE HealthCare rose to $564 million, up from $374 million in the previous year, resulting in a net income margin of 11.8%, compared to 8.0% from the prior year. Adjusted earnings before interest and taxes $(EBIT)$ was reported at $715 million, an increase from $681 million, with an adjusted EBIT margin of 15.0%, up from 14.7%. Diluted earnings per share $(EPS)$ improved to $1.23 from $0.81 the previous year, while adjusted EPS increased to $1.01 from $0.90. The company noted strong order growth, with organic orders increasing by a record 10% year-over-year, and a total company book-to-bill ratio of 1.09 times. GE HealthCare's cash flow from operating activities was $250 million, down from $419 million, with free cash flow at $98 million compared to $274 million the previous year. Additionally, the Board of Directors authorized a $1 billion share repurchase program as part of the company's strategic financial initiatives.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。